Assessment of Novel Antioxidant Therapy in Atherosclerosis by Contrast Ultrasound Molecular Imaging
| Autor: | Brian P. Davidson, Zaverio M. Ruggeri, José A. López, Jonathan R. Lindner, Yue Qi, Tamara Atkinson, Sherry Liang, William Packwood, Aris Xie |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Aortic Diseases Contrast Media Aorta Thoracic 030204 cardiovascular system & hematology Platelet membrane glycoprotein Antioxidants Article Endothelial activation Superoxide dismutase Mice 03 medical and health sciences 0302 clinical medicine Von Willebrand factor medicine.artery Animals Medicine Thoracic aorta Radiology Nuclear Medicine and imaging Platelet Ultrasonography Mice Knockout biology business.industry Atherosclerosis Molecular Imaging Mice Inbred C57BL Disease Models Animal Treatment Outcome 030104 developmental biology biology.protein Molecular imaging Cardiology and Cardiovascular Medicine business Lipoprotein |
| Zdroj: | Journal of the American Society of Echocardiography. 31:1252-1259.e1 |
| ISSN: | 0894-7317 |
| Popis: | BACKGROUND. We used ultrasound molecular imaging to evaluate the therapeutic effects of anti-oxidant therapy with EUK-207, which has superoxide dismutase and catalase activities, on suppressing high risk atherosclerotic features. METHODS. Mice with age-dependent atherosclerosis produced by deletion of the LDL-receptor and Apobec-1 were studied at 20 and 40 weeks of age. EUK-207 or vehicle was administered for the preceding 8 weeks. Therapy for 28 weeks was also studied for 40 week-old mice. Ultrasound molecular imaging of the thoracic aorta was performed with contrast agents targeted to endothelial P-selectin, von Willebrand factor (VWF) A1-domain, and platelet GPIbα; or control agent. Aortic plaque area and macrophage content were assessed by histology. RESULTS. In 20 week-old DKO mice, EUK-207 compared to sham therapy produced only non-significant trends for reduction in molecular imaging signal for endothelial P-selectin, VWF A1-domain and platelet adhesion. At 40 weeks, EUK-207 given for 8 or 28 weeks significantly (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|